Table 1.
Biologics approved by the FDA in 2022 [3].
| Trade Name a | Active Ingredient a | Class | Indication |
|---|---|---|---|
| BriumviTM | Ublituximab--xiiy | Monoclonal Antibody | Relapsed multiple sclerosis |
| DaxxifyTM | DaxibotulinumtoxinA-lanm | Protein (toxin) | Temporary improvement of moderate/severe glabellar lines (eyebrows) associated with corrugator and/or procerus muscle activity |
| ElahereTM | Mirvetuximab soravtansine-gynx | Antibody Drug Conjugate | Fallopian tube/primary peritoneal cancer resistant to platinum therapy |
| EnjaymoTM | Sutimlimab-jome | Monoclonal Antibody | Alleviation of red blood cell transfusion due to autoimmune hemolytic anemia |
| ImjudoTM | Tremelimumab-actl | Monoclonal Antibody | Unresectable hepatocellular carcinoma |
| KimmtrakTM | Tebentafusp-tebn | Bispecific Fusion Protein | Unresectable/metastatic uveal melanoma (eye cancer) |
| LunsumioTM | Osunetuzumab-axgb | Monoclonal Antibody | Relapsed/refractory follicular (non-Hodgkin) lymphoma in adults |
| NexoBridTM | Anacaulase-bcdb | Mixture of proteolytic enzymes | Debridement of burn wounds |
| OpdualagTM | Nivolumab & Relatlimab-rmbw | Combination of Monoclonal Antibodies | Unresectable/metastatic melanoma |
| RolvedonTM | Eflapegrastim-xnst | Hormone (glycoprotein) | Decrease in the incidence of infection, as manifested by Febrile Neutropenia, when receiving myelosuppressive anticancer drugs |
| SpevigoTM | Spesolimab-sbzo | Monoclonal Antibody | Pustular psoriasis flares |
| TecvayliTM | Teclistamab-cqyv | Bispecific Monoclonal Antibody | Relapsed/refractory multiple myeloma |
| TzieldTM | Teplizumab-mzwv | Monoclonal Antibody | Delay the onset of stages 2/3 type 1 diabetes |
| VabysmoTM | Faricimab-svoa | Bispecific Monoclonal Antibody | Neovascular age-related macular degeneration/diabetic macular edema |
| XenpozymeTM | Olipudase alfa-rpcp | Enzyme | Non-central nervous system (CNS) manifestations of acid sphingomyelinase deficiency |
a Trade name used in the USA.